Literature DB >> 9691919

Imipramine decreases oesophageal pain perception in human male volunteers.

P L Peghini1, P O Katz, D O Castell.   

Abstract

BACKGROUND: Visceral hyperalgesia is a hallmark of functional gastrointestinal disorders. Antidepressants improve symptoms in these patients, although their mode of action is unclear. Antidepressant, anticholinergic, and analgesic mechanisms have been proposed. AIMS: To investigate whether imipramine, which has a visceral analgesic effect, increases pain thresholds to experimental visceral pain.
METHODS: Visceral perception for first sensation and pain was measured with intraoesophageal balloon distension in 15 male volunteers. The effect of imipramine was studied in a double blind, placebo controlled, crossover study. Imipramine was given in ascending doses for 12 days (25 mg days 1-3, 50 mg days 4-6, 75 mg days 7-12), with oesophageal perception studied on day 13.
RESULTS: Inflation volumes and intraballoon pressures at first sensation were not different between placebo and imipramine. Balloon inflation volume at pain threshold was higher on imipramine (p = 0.015). Median intraballoon pressures were not different at pain threshold for placebo and imipramine. Oesophageal wall compliance was not affected by imipramine.
CONCLUSION: Increased pain thresholds on imipramine in this group of normal male volunteers in the absence of changes in oesophageal tone imply the presence of a visceral analgesic effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691919      PMCID: PMC1727141          DOI: 10.1136/gut.42.6.807

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds.

Authors:  K E Isenberg; T J Cicero
Journal:  Eur J Pharmacol       Date:  1984-08-03       Impact factor: 4.432

2.  Antinociceptive effect of intrathecally administered serotonin.

Authors:  J K Wang
Journal:  Anesthesiology       Date:  1977-09       Impact factor: 7.892

3.  Measurement of plasma levels of clomipramine in the treatment of chronic pain.

Authors:  J L Montastruc; M A Tran; M Blanc; J P Charlet; J David; M Mansat; J Cotonat; M Patacq-Sapijanskas; B Guiraud-Chaumeil; A Rascol
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

4.  Imipramine reduces experimental pain.

Authors:  B Bromm; W Meier; E Scharein
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

5.  Abnormal sensory perception in patients with esophageal chest pain.

Authors:  J E Richter; C F Barish; D O Castell
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

Review 6.  Pain relief by antidepressants: possible modes of action.

Authors:  Charlotte Feinmann
Journal:  Pain       Date:  1985-09       Impact factor: 6.961

7.  Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome.

Authors:  J Ritchie
Journal:  Gut       Date:  1973-02       Impact factor: 23.059

8.  Graded esophageal balloon distention. A new provocative test for noncardiac chest pain.

Authors:  C F Barish; D O Castell; J E Richter
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

9.  Therapeutic effects of antidepressants in chronic pain.

Authors:  R D France; J L Houpt; E H Ellinwood
Journal:  Gen Hosp Psychiatry       Date:  1984-01       Impact factor: 3.238

10.  Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system.

Authors:  M Botney; H L Fields
Journal:  Ann Neurol       Date:  1983-02       Impact factor: 10.422

View more
  36 in total

1.  Long-term outcome from tricyclic antidepressant treatment of functional chest pain.

Authors:  C Prakash; R E Clouse
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 2.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

4.  Optimal treatment of laryngopharyngeal reflux disease.

Authors:  Irene Martinucci; Nicola de Bortoli; Edoardo Savarino; Andrea Nacci; Salvatore Osvaldo Romeo; Massimo Bellini; Vincenzo Savarino; Bruno Fattori; Santino Marchi
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

Review 5.  Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome.

Authors:  Nicola de Bortoli; Irene Martinucci; Massimo Bellini; Edoardo Savarino; Vincenzo Savarino; Corrado Blandizzi; Santino Marchi
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

6.  Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus.

Authors:  Nikos Viazis; George Karamanolis; Eleni Vienna; Dimitrios G Karamanolis
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

7.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

8.  Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.

Authors:  Julajak Limsrivilai; Phunchai Charatcharoenwitthaya; Nonthalee Pausawasdi; Somchai Leelakusolvong
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

9.  Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn.

Authors:  M E Riehl; J E Pandolfino; O S Palsson; L Keefer
Journal:  Dis Esophagus       Date:  2015-03-30       Impact factor: 3.429

Review 10.  Current perspectives on the diagnosis and treatment of functional esophageal disorders.

Authors:  Roy Dekel; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.